

Int'l App. No.: PCT/US99/26746  
Int'l Filing Date: 12 November 1999

6. (Amended) A method according to claim 1, wherein the plasma concentration of the insulin sensitiser remains substantially within the range from the Minimum Threshold Plasma Concentration to a level at or above the Preferred Threshold Plasma Concentration.

8. (Amended) A method according to claim 7, wherein the insulin sensitiser is Compound (I) and the SC50 is within the range of 40 to 65 ng/mL.

10. (Amended) A method according to claim 7, wherein the insulin sensitiser is Compound (I) and the Preferred Threshold Plasma Concentration is in the range of about 80 to about 130 ng/mL or about 82.2 to about 123.4ng/mL.

15. (Amended) A method according to any one of claims 1 to 6, wherein the insulin sensitiser is selected from the group consisting of: 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone), 5-[4-[(1-methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-dione (or ciglitazone), 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone) and 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl]thiazolidine-2,4-dione (or englitazone).

19. (Amended) A modified release composition according to claim 18 being a delayed, pulsed or sustained release composition.

20. (Amended) A composition according to claim 16, adapted to provide a method of treatment according to claim 1.